Antimalignancy responses
| Response . | Number of patients (%) . |
|---|---|
| ORR | 9 (43) |
| CR | 1 (4.8) |
| PR | 8 (38) |
| SD | 11 (52) |
| PD | 1 (4.8) |
| Median (95% CI) | |
| Duration of response, weeks∗ | 8.9 (8.7-NE) |
| EFS, weeks† | 13 (11-17) |
| Overall survival, weeks‡ | 134 (81-NE) |
| Response . | Number of patients (%) . |
|---|---|
| ORR | 9 (43) |
| CR | 1 (4.8) |
| PR | 8 (38) |
| SD | 11 (52) |
| PD | 1 (4.8) |
| Median (95% CI) | |
| Duration of response, weeks∗ | 8.9 (8.7-NE) |
| EFS, weeks† | 13 (11-17) |
| Overall survival, weeks‡ | 134 (81-NE) |
CI, confidence interval; NE, cannot be estimated.
Duration of response for patients achieving PR or CR, defined as time from achieving first response of PR or CR until lymphoma progression, start of additional therapy, or death.
EFS, defined as time from CAR T-cell infusion until lymphoma progression, start of additional therapy, or death.
Overall survival was defined as time from CAR T-cell infusion until death; 11 patients were still surviving at last follow-up.